ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company primarily offers First Defense, an orally delivered scours preventive product for newborn calves. It also provides California Mastitis Test, which is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing purified Nisin treatment for subclinical mastitis in lactating dairy cows; and selling various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to animal health distributors, fleet stores, and direct to farms. The company was founded in 1982 and is headquartered in Portland, Maine.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone207-878-2770
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.99 million
Profitability
Miscellaneous
Employees47
OptionableNot Optionable
ImmuCell (NASDAQ:ICCC) Frequently Asked Questions
What is ImmuCell's stock symbol?
ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."
How were ImmuCell's earnings last quarter?
ImmuCell Co. (NASDAQ:ICCC) issued its quarterly earnings results on Wednesday, February, 13th. The biotechnology company reported ($0.19) EPS for the quarter. The biotechnology company earned $2.94 million during the quarter. ImmuCell had a negative net margin of 21.13% and a negative return on equity of 7.65%. View ImmuCell's Earnings History.
When is ImmuCell's next earnings date?
Has ImmuCell been receiving favorable news coverage?
News articles about ICCC stock have trended somewhat positive recently, InfoTrie reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. ImmuCell earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of ImmuCell's key competitors?
Who are ImmuCell's key executives?
ImmuCell's management team includes the folowing people:
- Mr. Michael F. Brigham, Pres, CEO, Treasurer, Sec. & Director (Age 58)
- Dr. Joseph H. Crabb, VP & Chief Scientific Officer (Age 64)
- Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 42)
- Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 63)
- Mr. A. Gustavo Scaffa, Sr. Director of Quality
Who are ImmuCell's major shareholders?
ImmuCell's stock is owned by many different of retail and institutional investors. Top institutional investors include Essex Financial Services Inc. (0.38%). Company insiders that own ImmuCell stock include Brian L Pessin and David Scott Tomsche. View Institutional Ownership Trends for ImmuCell.
Which major investors are selling ImmuCell stock?
How do I buy shares of ImmuCell?
Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ImmuCell's stock price today?
One share of ICCC stock can currently be purchased for approximately $7.12.
How big of a company is ImmuCell?
ImmuCell has a market capitalization of $39.09 million and generates $10.99 million in revenue each year. ImmuCell employs 47 workers across the globe.
What is ImmuCell's official website?
How can I contact ImmuCell?
ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]
MarketBeat Community Rating for ImmuCell (NASDAQ ICCC)
MarketBeat's community ratings are surveys of what our community members think about ImmuCell and other stocks. Vote "Outperform" if you believe ICCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICCC will underperform the S&P 500 over the long term. You may vote once every thirty days.
